[go: up one dir, main page]

NO20033677L - 2-arylaminopyrimidiner for behandling av GSK3-relaterte sykdommer - Google Patents

2-arylaminopyrimidiner for behandling av GSK3-relaterte sykdommer

Info

Publication number
NO20033677L
NO20033677L NO20033677A NO20033677A NO20033677L NO 20033677 L NO20033677 L NO 20033677L NO 20033677 A NO20033677 A NO 20033677A NO 20033677 A NO20033677 A NO 20033677A NO 20033677 L NO20033677 L NO 20033677L
Authority
NO
Norway
Prior art keywords
treatment
arylaminopyrimidines
gsk3
related diseases
solution
Prior art date
Application number
NO20033677A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033677D0 (no
Inventor
Stefan Berg
Sven Hellberg
Ratan Bhat
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20033677D0 publication Critical patent/NO20033677D0/no
Publication of NO20033677L publication Critical patent/NO20033677L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NO20033677A 2001-02-20 2003-08-19 2-arylaminopyrimidiner for behandling av GSK3-relaterte sykdommer NO20033677L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26990301P 2001-02-20 2001-02-20
PCT/SE2002/000270 WO2002066480A2 (fr) 2001-02-20 2002-02-18 2-arylamino-pyrimidines pour le traitement de troubles associes a gsk3

Publications (2)

Publication Number Publication Date
NO20033677D0 NO20033677D0 (no) 2003-08-19
NO20033677L true NO20033677L (no) 2003-10-02

Family

ID=23029104

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033677A NO20033677L (no) 2001-02-20 2003-08-19 2-arylaminopyrimidiner for behandling av GSK3-relaterte sykdommer

Country Status (16)

Country Link
US (1) US7078410B2 (fr)
EP (1) EP1423388B1 (fr)
JP (1) JP4309657B2 (fr)
KR (1) KR20030076688A (fr)
CN (1) CN100415744C (fr)
AT (1) ATE416175T1 (fr)
BR (1) BR0207096A (fr)
CA (1) CA2435177A1 (fr)
DE (1) DE60230160D1 (fr)
ES (1) ES2316546T3 (fr)
IL (1) IL156784A0 (fr)
MX (1) MXPA03007266A (fr)
NO (1) NO20033677L (fr)
NZ (1) NZ527009A (fr)
WO (1) WO2002066480A2 (fr)
ZA (1) ZA200306175B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2004014382A1 (fr) 2002-07-29 2004-02-19 Rigel Pharmaceuticals Procede de traitement ou de prevention de maladies auto-immunes au moyen de composes de 2,4-pyrimidinediamine
CA2508194C (fr) * 2002-12-03 2011-05-24 Kyorin Pharmaceutical Co., Ltd. Utilisation d'ibudilast en tant qu'inhibiteur d'une phosphodiesterase 10a
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
EP1670460B1 (fr) 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP2008515986A (ja) * 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CA2589793A1 (fr) * 2004-12-17 2006-06-22 Astrazeneca Ab 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides en tant qu'inhibi teurs de cdk
US20060204980A1 (en) * 2004-12-28 2006-09-14 Altieri Dario C Colorectal cancer therapies
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006128184A2 (fr) * 2005-05-20 2006-11-30 Alantos-Pharmaceuticals, Inc. Inhibiteurs de metalloprotease heterobicyclique
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
EP1942897A1 (fr) * 2005-10-03 2008-07-16 AstraZeneca AB Utilisation de derives de pyrimidine dans la production d'un medicament pour la prevention et/ou le traitement de la maladie d'alzheimer
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
KR20080104351A (ko) * 2006-03-31 2008-12-02 노파르티스 아게 유기 화합물
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
CA2654670A1 (fr) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh Nouveaux composes
WO2008068171A1 (fr) * 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Pyrimidines substituées et leur utilisation en tant que modulateurs de jnk
WO2008078091A1 (fr) 2006-12-22 2008-07-03 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
HRP20170317T1 (hr) 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010002985A1 (fr) 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Modulateurs de l’expression de la protéine bmi-1
WO2010009139A2 (fr) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Composés inhibiteurs de pyrimidine imidazolyle
CA2728228A1 (fr) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Composes inhibiteurs de l'oxindolyle
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
TW201022262A (en) * 2008-10-29 2010-06-16 Astrazeneca Ab Novel compounds 515
CN101735211B (zh) * 2008-11-04 2012-11-14 复旦大学 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途
AU2010237100A1 (en) 2009-04-15 2011-10-27 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as Alzheimer's disease
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP2012529514A (ja) 2009-06-08 2012-11-22 ギリアード サイエンシーズ， インコーポレイテッド シクロアルキルカルバメートベンズアミドアニリンｈｄａｃ阻害剤化合物
BRPI1010884A2 (pt) 2009-06-08 2016-03-15 Gilead Sciences Inc composto inibidores hdac de alcanoilamino benzamida anilina
US20120220581A1 (en) 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
CN102391264A (zh) * 2011-09-21 2012-03-28 河北九派制药有限公司 6-溴咪唑并[1,2-a]吡啶的制备方法
EP2671885A1 (fr) 2012-06-05 2013-12-11 Ares Trading S.A. Dérivés imidazo-thiadiazole et imidazo-thiadiazole
CN104411312B (zh) 2012-06-26 2018-03-06 詹森药业有限公司 包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]三唑[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合
JP6174695B2 (ja) 2012-07-09 2017-08-02 ヤンセン ファーマシューティカ エヌ．ベー． ホスホジエステラーゼ１０酵素の阻害剤
SG11201503299YA (en) 2012-09-28 2015-06-29 Univ Vanderbilt Fused heterocyclic compounds as selective bmp inhibitors
HK1215032A1 (zh) 2012-11-21 2016-08-12 Ptc Therapeutics, Inc. 取代的反向嘧啶bmi-1抑制劑
AU2013399092A1 (en) 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
WO2015076800A1 (fr) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Inhibiteurs de bmi-1 à base de pyridine et de pyrazine substituées
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN106362155A (zh) * 2016-10-08 2017-02-01 无锡汉强医药科技有限公司 Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用
MX2019007120A (es) 2016-12-16 2019-09-16 Basf Se Compuestos plaguicidas.
EP3765460A1 (fr) 2018-03-14 2021-01-20 Vanderbilt University Inhibition de la signalisation bmp, composés, compositions et leurs utilisations
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
KR102249521B1 (ko) 2018-11-14 2021-05-07 아이알링크 주식회사 스마트폰과 동기화되는 pc 인터페이스 장치 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135699T1 (de) * 1986-01-13 1996-04-15 American Cyanamid Co 4,5,6-substituierte 2-pyrimidinamine
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
WO2002020495A2 (fr) * 2000-09-06 2002-03-14 Chiron Corporation Inhibiteurs de glycogene-synthase kinase 3

Also Published As

Publication number Publication date
JP4309657B2 (ja) 2009-08-05
IL156784A0 (en) 2004-02-08
US20040106574A1 (en) 2004-06-03
ZA200306175B (en) 2005-01-26
ATE416175T1 (de) 2008-12-15
WO2002066480A3 (fr) 2004-04-01
BR0207096A (pt) 2004-01-20
EP1423388B1 (fr) 2008-12-03
JP2004522777A (ja) 2004-07-29
DE60230160D1 (de) 2009-01-15
EP1423388A2 (fr) 2004-06-02
NO20033677D0 (no) 2003-08-19
MXPA03007266A (es) 2003-12-04
CA2435177A1 (fr) 2002-08-29
CN1823064A (zh) 2006-08-23
CN100415744C (zh) 2008-09-03
KR20030076688A (ko) 2003-09-26
ES2316546T3 (es) 2009-04-16
NZ527009A (en) 2006-04-28
WO2002066480A2 (fr) 2002-08-29
US7078410B2 (en) 2006-07-18
HK1094697A1 (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
NO20033677D0 (no) 2-arylaminopyrimidiner for behandling av GSK3-relaterte sykdommer
DE59603187D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen, bei dem die gebildeten salze ausgefällt werden
ATE546135T1 (de) Hyaluronsäure-nanopartikel
WO2002085951A3 (fr) Chitosane partiellement o-acetyle, partiellement n-acetyle substitue de maniere aleatoire soluble dans l'eau, des preparations de conservation contenant des chitosanes et des procedes de fabrication de ceux-ci
BR0108734A (pt) Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas
CA2527120A1 (fr) Solution aqueuse stable d'un fongicide a base de natamycine
MXPA01008283A (es) Composiciones de polisacaridos y uso de las mismas.
ATE223649T1 (de) Mittel zum eintauchen von zitzen
SE0003544L (sv) Förfarande för framställning av en absorberande sanitetsartikel som innefattar mjölksyraproducerande bakterier samt sådant alster
BRPI0416088A (pt) composição, sistema, e método de tratar condições tais como calcificação vascular
CA2015235A1 (fr) Povidone-iode utilise comme agent prophylactique antimicrobien ophtalmique chez les nouveau-nes
CA2529441A1 (fr) Utilisation d'acide hyaluronique dans la preparation de compositions pour le traitement d'aphtes de la cavite buccale
WO2002067952A8 (fr) Traitement prophylactique de tetines
TW200519080A (en) Agent containinf (2R)-2-propyloctanic acid as effective component
WO2001093910A3 (fr) Procede pour augmenter le potentiel d'antioxydation de solutions aqueuses contenant du selenium
WO2002070404A3 (fr) Solutions d'acide hypobromeux stabilisees
WO2000038660A3 (fr) Utilisation de bisphosphonates pour la prophylaxie et le traitement de processus infectieux
HUP0101177A2 (hu) Glikogén alkalmazása mesterséges könnyként felhasználható oldat előállítására
KR960030812A (ko) 취반용 기능미의 제조방법
BRPI0416427A (pt) suspensão aquosa e método de preparação de suspensão aquosa
SE0101307L (sv) Effervescent fastämneskomposition
WO2003024996A3 (fr) Macrocycles antibacteriens
BR0304303A (pt) Composição para um sistema espessante hidrofóbico de viscosidade reduzida para o espessamento de um sistema aquoso contendo polìmero, e, métodos para fornecer um sistema espessante de viscosidade reduzida para um sistema aquoso contendo polìmero e para aumentar a viscosidade de um sistema aquoso contendo polìmero
PL378216A1 (pl) Przeciwbakteryjna kompozycja do miejscowego stosowania na błony śluzowe i skórę
DE60013583T8 (de) Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs